Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Want to see FHTX full AI Analyst Report?
Top Page
Foghorn Therapeutics
(NASDAQ:FHTX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$5.00
▼(-5.48% Downside)
Action:ReiteratedDate:04/22/26
The score is held back primarily by weak financial performance—large ongoing losses, heavy cash burn, and negative equity—despite some revenue rebound. Technicals are moderately supportive with price above major moving averages, and corporate events add a positive offset via trial progress and improved runway, but valuation remains constrained by loss-making fundamentals and no dividend support.
Positive Factors
Proprietary chromatin-targeting platform
Foghorn’s Gene Traffic Control platform focuses on chromatin regulators (SMARCA2, CBP, EP300, ARID1B), enabling a pipeline of first‑in‑class, target-specific programs. A platform approach supports repeatable discovery, diversified clinical candidates, and durable scientific differentiation across oncology indications.
Negative Factors
High cash burn
Sustained negative operating and free cash flow of roughly -$86M in 2025 signals ongoing heavy cash burn tied to R&D. This structural cash consumption necessitates repeated external financing or partner funding, raising dilution and execution risk and constraining strategic flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary chromatin-targeting platform
Foghorn’s Gene Traffic Control platform focuses on chromatin regulators (SMARCA2, CBP, EP300, ARID1B), enabling a pipeline of first‑in‑class, target-specific programs. A platform approach supports repeatable discovery, diversified clinical candidates, and durable scientific differentiation across oncology indications.
Read all positive factors
Foghorn Therapeutics (FHTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$279.41M
Dividend YieldN/A
Average Volume (3M)157.41K
Price to Earnings (P/E)―
Beta (1Y)1.65
Revenue Growth36.75%
EPS Growth27.97%
CountryUS
Employees112
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.35
Shares Outstanding58,700,245
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue7.76
Enterprise Value/Gross Profit26.05
Enterprise Value/Ebitda-3.29
Forecast
1Y Price Target
$11.67Price Target Upside120.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$33.29M
Foghorn Therapeutics Business Overview & Revenue Model
Company Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control pla...
How the Company Makes Money
As a clinical-stage biotechnology company, Foghorn Therapeutics primarily funds operations through (1) external financing (e.g., equity offerings) and (2) collaboration-related revenue when applicable (such as payments from strategic partnerships)...
Foghorn Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
17
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.91M | 22.60M | 34.16M | 19.23M | 1.32M |
| Gross Profit | 27.58M | 22.60M | 34.16M | 19.23M | 1.32M |
| EBITDA | -78.78M | -97.17M | -104.45M | -113.82M | -96.19M |
| Net Income | -74.28M | -86.62M | -98.43M | -108.88M | -101.32M |
Balance Sheet | |||||
| Total Assets | 198.10M | 283.98M | 285.92M | 404.88M | 519.77M |
| Cash, Cash Equivalents and Short-Term Investments | 158.89M | 243.75M | 234.06M | 345.80M | 154.29M |
| Total Debt | 41.27M | 37.13M | 45.07M | 51.51M | 58.33M |
| Total Liabilities | 306.60M | 329.51M | 363.11M | 404.77M | 422.90M |
| Stockholders Equity | -108.50M | -45.53M | -77.19M | 112.00K | 96.87M |
Cash Flow | |||||
| Free Cash Flow | -86.15M | -101.31M | -119.33M | 192.40M | -53.56M |
| Operating Cash Flow | -86.10M | -100.41M | -118.11M | 193.61M | -50.25M |
| Investing Cash Flow | 112.04M | -29.90M | 144.45M | -244.32M | 36.17M |
| Financing Cash Flow | 1.02M | 105.43M | 1.78M | 1.76M | 22.42M |
Foghorn Therapeutics Technical Analysis
Positive
5.29
Price Trends
5.22
Positive
5.23
Positive
5.09
Positive
Market Momentum
-0.07
Negative
58.29
Neutral
66.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FHTX, the sentiment is Positive. The current price of 5.29 is above the 20-day moving average (MA) of 4.85, above the 50-day MA of 5.22, and above the 200-day MA of 5.09, indicating a bullish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 58.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FHTX.
Foghorn Therapeutics Risk Analysis
Foghorn Therapeutics disclosed 53 risk factors in its most recent earnings report. Foghorn Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Foghorn Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.50B | -33.72 | -15.12% | ― | 63.54% | 40.61% | |
53 Neutral | $1.82B | -8.74 | -269.56% | ― | 550.00% | -107.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $279.41M | -4.58 | 88.31% | ― | 36.75% | 27.97% | |
48 Neutral | $176.15M | -1.07 | -60.15% | ― | 29.85% | 99.59% |
* Healthcare Sector Average
FHTX
Foghorn Therapeutics
4.76
0.60
14.42%
TNXP
Tonix Pharma
12.40
-5.64
-31.26%
GLUE
Monte Rosa Therapeutics
18.72
13.82
282.04%
INBX
Inhibrx Biosciences Inc
124.82
112.50
913.15%
Foghorn Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Foghorn Highlights Preclinical Chromatin Oncology Advances at AACR
Positive
Apr 21, 2026
On April 21, 2026, Foghorn Therapeutics announced preclinical data for several oncology programs presented at the 2026 American Association for Cancer Research Annual Meeting, including its selective SMARCA2 inhibitor FHD-909 and selective CBP, EP...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingProduct-Related Announcements
Foghorn Advances FHD-909 Trial and Strengthens Financial Position
Positive
Mar 12, 2026
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression, with an initial emphasis on oncology. Using its Gene Traffic Control platform, the company is...
Business Operations and StrategyExecutive/Board Changes
Foghorn Therapeutics Names Veteran Executive as New CFO
Positive
Feb 23, 2026
On February 23, 2026, Foghorn Therapeutics appointed veteran finance executive Ryan D. Maynard as chief financial officer, with immediate effect, replacing interim CFO Jeff Sacher. Maynard assumes the roles of principal financial and accounting of...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.